Trial · NCT00120523
Results by group290
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 290
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Safety Assessed by Adverse Events | Pimecrolimus | Acute tonsillitis | 8.6 | percentage of participants | |
| Safety Assessed by Adverse Events | Topical Corticosteroids | Acute tonsillitis | 7.8 | percentage of participants | |
| Safety Assessed by Adverse Events | Pimecrolimus | Allergy to arthropod bite | 5.9 | percentage of participants | |
| Safety Assessed by Adverse Events | Topical Corticosteroids | Allergy to arthropod bite | 4.9 | percentage of participants | |
| Safety Assessed by Adverse Events | Pimecrolimus | Arthropod bite | 7.1 | percentage of participants | |
| Safety Assessed by Adverse Events | Topical Corticosteroids | Arthropod bite | 8.8 | percentage of participants | |
| Safety Assessed by Adverse Events | Pimecrolimus | Asthma | 15.1 | percentage of participants | |
| Safety Assessed by Adverse Events | Topical Corticosteroids | Asthma | 14.6 | percentage of participants | |
| Safety Assessed by Adverse Events | Pimecrolimus | Bronchiolitis | 5.4 | percentage of participants | |
| Safety Assessed by Adverse Events | Topical Corticosteroids | Bronchiolitis | 5.7 | percentage of participants | |
| Safety Assessed by Adverse Events | Pimecrolimus | Bronchitis | 36.3 | percentage of participants | |
| Safety Assessed by Adverse Events | Topical Corticosteroids | Bronchitis | 33.8 | percentage of participants | |
| Safety Assessed by Adverse Events | Pimecrolimus | Bronchospasm | 5.2 | percentage of participants | |
| Safety Assessed by Adverse Events | Topical Corticosteroids | Bronchospasm | 6.7 | percentage of participants | |
| Safety Assessed by Adverse Events | Pimecrolimus | Conjunctivitis | 16.5 | percentage of participants | |
| Safety Assessed by Adverse Events | Topical Corticosteroids | Conjunctivitis | 16.2 | percentage of participants | |
| Safety Assessed by Adverse Events | Pimecrolimus | Conjunctivitis allergic | 5.0 | percentage of participants | |
| Safety Assessed by Adverse Events | Topical Corticosteroids | Conjunctivitis allergic | 6.3 | percentage of participants | |
| Safety Assessed by Adverse Events | Pimecrolimus | Constipation | 6.9 | percentage of participants | |
| Safety Assessed by Adverse Events | Topical Corticosteroids | Constipation | 6.7 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00120523/results